FDA Memo Sheds Light On Plan B Discussions
FDA received a dual Rx/OTC marketing plan from Barr for its emergency contraceptive Plan B several weeks before issuing a "not approvable" letter last spring, an internal agency memorandum reveals
FDA received a dual Rx/OTC marketing plan from Barr for its emergency contraceptive Plan B several weeks before issuing a "not approvable" letter last spring, an internal agency memorandum reveals